Full Press Release Details
Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
FRANCISCO, CALIFORNIA, January 27, 2025 /Globe newswire/ - GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical
stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK)
cell engager TriKE platform, today announced that the first patient was dosed in a Phase 1 trial evaluating GTB-3650,
its second-generation TriKE, for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies.
are thrilled to initiate patient dosing with GTB-3650 in the Phase 1 trial to evaluate the potential in patients with hematological malignancies,
which represents a significant milestone for the company. As we continue to progress through clinical development, we eagerly anticipate
sharing initial data from the study in 2025", said Michael Breen, Executive Chairman and interim Chief Executive Officer of GT
is GT Biopharma's wholly owned second-generation TriKE. It utilizes camelid nanobody technology, with the potential to improve
potency and enhance binding affinity. The Phase 1 dose escalation study will evaluate GTB-3650 in up to approximately 14 patients (seven
cohorts) with relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia (AML)
and high-risk myelodysplastic syndrome (MDS). GTB-3650 will be dosed in two-week blocks, two weeks on and two weeks off, for up to four
months based on clinical benefit. The trial will assess safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient
NK cells and clinical activity. More details can be found on clinicaltrials.gov with the identifier: NCT06594445.
Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic
products based on our proprietary TriKE NK cell engager platform. Our TriKE platform is designed to harness and enhance the
cancer killing abilities of a patient's immune system's natural killer cells. GT Biopharma has an exclusive worldwide license
agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. For more information,
please visit gtbiopharma.com.
statements in this press release may constitute "forward-looking statements" regarding future events and our future results.
All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These
statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs
and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals,"
"projects", "intends," "plans," "believes," "seeks," "estimates,"
"endeavors," "strives," "may," or variations of such words, and similar expressions are intended
to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks,
uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and
adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our
most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other
reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking
statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the
result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and
Exchange Commission.
is a registered trademark owned by GT Biopharma, Inc.